AvantGen is a biotechnology company with therapeutic and bioscience divisions. The firm's proprietary and robust yeast display system, large human antibody database, multiple fully human antibody (Germliner™) libraries and screening technologies - AvantGen's Therapeutic Division (ATD) - are structured around novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization, for therapeutic development as well as discovery of antibodies with novel formats for immunotherapy. AvantGen collaborates with pharmaceutical and biotechnology companies to facilitate and speed their path to antibody-based therapeutic development through services, partnerships, and licensing. Additionally, by combining AvantGen's yeast display system and the superior immune responses in rabbits, AvantGen has developed a novel platform to generate rabbit monoclonal antibodies with superior affinity and specificity. With this platform, AvantGen's Bioscience Division (ABD) is developing high quality rabbit monoclonal antibodies for high value diagnostic targets. The firm has developed novel antibodies against various targets for therapeutic, diagnostic development and successfully completed de novo antibody screening, antibody humanization and optimization projects for pharmaceutical and biotech companies, as well as academic institutions.
